Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.
James Rochon, Petr Protiva, Leonard B Seeff...
https://pubmed.ncbi.nlm.nih.gov/18798340/Actively Recruiting
Led by Duke University · Updated on 2026-04-08
400
Participants Needed
6
Research Sites
N/A
Total Duration
This research aims to create a nationwide registry of patients who have experienced severe drug-induced liver injury DILI to help understand this condition better. The study focuses on collecting and storing biological samples like serum, DNA, and lymphocytes from these patients. The goal is to build a clinical database and specimen bank to support future research into why some people develop severe DILI. This effort is part of the Drug-Induced Liver Injury Network DILIN established by the National Institute of Diabetes and Digestive and Kidney Diseases NIDDK. The study retrospectively identifies individuals who had severe DILI episodes due to drugs or herbal and dietary supplements HDSCAM starting from January 1, 1994. Researchers collect clinical information and biological specimens, including immortalized lymphocytes that provide ongoing access to DNA and living immune cells for analysis. The study maintains a registry with yearly updates to allow recontacting participants for future research. Participants provide medical information and blood samples for genetic and other analyses. Researchers track and update contact details annually to facilitate future studies. The primary outcome is to maintain this registry through July 2028. The study involves no investigational treatments but focuses on gathering data and samples for ongoing and future mechanistic investigations into severe DILI.
CONDITIONS
Drug-Induced Liver Injury (DILI) Network Retrospective
E
Eilene Pham
M
Matt Baum
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Duke University
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm eligibility and collect initial information
Duration - One-time data and sample collection
Participants provide medical information and biological specimens to help establish and maintain a clinical database and specimen bank related to drug-induced liver injury.
1 visit (in-person) for medical record review and sample collection
Duration - Up to several years with yearly updates
Participants are registered and their contact information is updated yearly to allow for future recontact and follow-up studies.
Annual contact updates (remote or in-person) to maintain registry information
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
James Rochon, Petr Protiva, Leonard B Seeff...
https://pubmed.ncbi.nlm.nih.gov/18798340/Duke University
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor